Thank you for your interest in post-marketing study information. The Post-Marketing Study Registration System on this website has ceased updates as of January 1, 2025, and related information is no longer provided on this platform.

For inquiries about post-marketing studies or related research information, we recommend exploring other resources that provide clinical trial information, such as the Taiwan Clinical Trials (TaiwanClinicalTrials.tw), clinical trial centers at major hospitals, or the website of Center for Drug Evaluation (https://www1.cde.org.tw/ct_taiwan/introduction.html).

We appreciate your understanding and continued support!

Company Name	Title of Study	Update Date
Daiichi Sankyo Taiwan Ltd.	A Retrospective, Non-interventional, Multicenter Study to Investigate the Prevalence of HER2 IHC 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan –The HERGYN Study	2024-11-05
Astellas Pharma Taiwan, Inc.	A Comparison Between Gilteritinib in Phase 3 Trials Versus Real- World External Comparator Cohort of Relapsed/Refractory (R/R) FLT3m+ Acute Myeloid Leukemia (AML) Patients After Hematopoietic Stem Cell Transplantation (HSCT)	2024-10-23
AstraZeneca Taiwan Ltd	iCaReMe Global Registry Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases	2024-10-23
AbbVie Biopharmaceuticals GmbH Taiwan Branch	A Multi-country, Post Marketing Observational Study of DME Patients with Suboptimal Response to anti-VEGF who are initiated with Dexamethasone intravitreal implant (DEX-I)	2024-07-05
Sanofi	PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study	2024-10-23
Novo Nordisk Pharma (Taiwan) Ltd.	Multicentre, single-arm, non-interventional regulatory post-marketing surveillance (rPMS) study to evaluate the safety and effectiveness of Saxenda® for weight management in routine clinical practice in Taiwan	2024-07-05
Bayer Taiwan Company Ltd.	REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immuno-oncology immune checkpoint inhibitor combination in first-line.	2024-07-05
Janssen Taiwan	Multicenter, Post-authorization Safety Study to Collect Disease Outcome Information from Taiwanese Research Participants with Niemann-Pick Disease Type C	2024-07-05
Bayer Taiwan Co., Ltd.	FINE-REAL: A non-interventional study providing insights into the use of finerenone in a routine clinical setting	2024-07-05
Pfizer Limited	Real world evaluation of COVID-19 burden and nirmatrelvir/ritonavir in Taiwan using National Health Insurance Research Database	2024-07-05